Person:
Lozano Borregón, Daniel

Profile Picture
First Name
Daniel
Last Name
Lozano Borregón
URI
https://hdl.handle.net/20.500.14352/77556
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Farmacia
Department
Química en Ciencias Farmacéuticas
Area
Química Inorgánica
Identifiers
UCM identifierORCIDScopus Author IDWeb of Science ResearcherIDDialnet IDGoogle Scholar ID

Filters

2022 - 20232
Reset filters

Settings

Has files: true × Subject: 615.371 ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Non-replicative antibiotic resistance-free DNA vaccine encoding S and N proteins induces full protection in mice against SARS-CoV-2
    (Frontiers in Immunology, 2022) Alcolea Alcolea, Pedro José; Larraga, Jaime; Rodríguez-Martín, Daniel; Alonso, Ana; Loayza, Francisco; Rojas, José M.; Ruiz García, Silvia; Louloudes Lázaro, Andrés; Carlón, Ana B.; Sánchez Cordón, Pedro José; Nogales Altozano, Pablo; Redondo, Natalia; Manzano García, Miguel; Lozano Borregón, Daniel; Palomero, Jesús; Montoya, María; Vallet Regí, María Dulce Nombre; Martín García, Verónica; Sevilla, Noemí; Larraga, Vicente
    SARS-CoV-2 vaccines currently in use have contributed to controlling the COVID-19 pandemic. Notwithstanding, the high mutation rate, fundamentally in the spike glycoprotein (S), is causing the emergence of new variants. Solely utilizing this antigen is a drawback that may reduce the efficacy of these vaccines. Herein we pre ent a DNA vaccine candidate that contains the genes encoding the S and the nucleocapsid (N) proteins implemented into the nonreplicative mammalian expression plasmid vector, pPAL. This plasmid lacks antibiotic resistance genes and contains an alternative selectable marker for production. The S gene sequence was modified to avoid furin cleavage (Sfs). Potent humoral and cellular immune responses were observed in C57BL/6J mice vaccinated with pPAL-Sfs + pPAL-N following a prime/boost regimen by the intramuscular route applying in vivo electroporation. The immunogen fully protected K18-hACE2 mice against a lethal dose (105 PFU) of SARS-CoV-2. Viral replication was completely controlled in the lungs, brain, and heart of vaccinated mice. Therefore, pPAL-Sfs + pPAL-N is a promising DNA vaccine candidate for protection from COVID-19.
  • Thumbnail Image
    Item
    An overview of the use of nanoparticles in vaccine development
    (Nanomaterials, 2023) Lozano Borregón, Daniel; Larraga, Vicente; Vallet Regí, María Dulce Nombre; Manzano García, Miguel
    Vaccines represent one of the most significant advancements in public health since they prevented morbidity and mortality in millions of people every year. Conventionally, vaccine technology focused on either live attenuated or inactivated vaccines. However, the application of nanotechnology to vaccine development revolutionized the field. Nanoparticles emerged in both academia and the pharmaceutical industry as promising vectors to develop future vaccines. Regardless of the striking development of nanoparticles vaccines research and the variety of conceptually and structurally different formulations proposed, only a few of them advanced to clinical investigation and usage in the clinic so far. This review covered some of the most important developments of nanotechnology applied to vaccine technologies in the last few years, focusing on the successful race for the preparation of lipid nanoparticles employed in the successful anti-SARS-CoV-2 vaccines.